Using HLA LOH as a Biomarker in Targeting Cancers: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
Improving Personalized Cell Therapies for Solid Tumors
Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.
Autologous Adipose Stem Cells Safe in Alzheimer Disease, More Efficacy Data Needed
Autologous adipose stem cell data in a small cohort provides a feasibility for future validation studies.
Managing CAR T-Associated Neurotoxicity and CRS: Bijal Shah, MD, MS; Michael Wang, MD
The hematologists from Moffitt Cancer Center and MD Anderson discussed managing CAR T-cell therapy-associated toxicities.
Using Polygenic Risk Score to Better Outcomes in Primary Open-Angle Glaucoma
Current studies are using a polygenic risk score to evaluate the risk and clinical outcomes in primary open-angle glaucoma (POAG).
CAR T-Cell Therapy Shows Efficacy and Safety in B-Cell Malignancies
Adicet Bio reported positive interim data from the phase 1 GLEAN study.
Reprogramming the Immune System for Kidney Transplant and Scleroderma
Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the company’s goal to reprogram the immune system.
Celularity, Imugene Collaboration to Focus on CAR T in Solid Tumors
The companies will combine Imugene’s CF33-CD19 oncolytic virus and Celularity’s investigational placental-derived CAR T-cell therapy.
Gene Therapy for Diabetic Macular Edema Shows Mixed Efficacy, Safety
Findings from the phase 2 INFINITY trial identified dose-dependent safety outcomes of ADVM-022 in patients with diabetic macular edema.
More Research Needed to Understand COVID-19 Vaccine Effects in CAR T Recipients
Further understanding of how COVID-19 vaccinations affect CAR T-cell therapy recipients is needed.
Gene Therapy for Sanfilippo Syndrome: Latest Updates
Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed LYS-SAF302, its mechanism of action, trial data, and further research.
Challenges in R/R LBC Lymphoma After CAR T Therapy
Julio Chavez, MD, MD, discussed treatment options for LBCL after relapsing on CAR T-cell therapy.
Importance of Screening and Early Treatment in Genetic Disorders: Paul Wuh-Liang Hwu, MD, PhD
The professor from National Taiwan University Hospital discussed gene therapy studies in AADC deficiency, Parkinson disease, SMA, and Pompe disease.
GeneTherapyLive’s Weekly Rewind – December 3, 2021
Review top news and interview highlights from the week ending December 3, 2021.
CAR T-Cell Therapy gets Orphan Drug Designation for Acute Lymphoblastic Leukemia
The cell therapy is approved for B-cell non-Hodgkin lymphoma and B-ALL in China.
Identifying Future Patients for Tmod Cell Therapy in BASECAMP-1: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
American Gene Technology’s Cell Therapy Continues to Show Safety in HIV
An independent Data Safety and Monitoring Board has recommended that the phase 1 RePAIR trial continue at an accelerated pace.
Mesenchymal Stem Cells and Other Upcoming Treatments for Progressive MS: Jeffrey Cohen, MD
The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed upcoming new therapies for relapsing MS.
New Treatment Post-Tisagenlecleucel Being Developed for Patients With LBC Lymphoma
Two sites in California and Missouri are actively recruiting patients with r/r LBCL who were treated with tisagenlecleucel to receive efineptakin alfa in the study.
IND Accepted for Sickle Cell Disease Cell Therapy
Beam Therapeutics will assess the safety and efficacy of BEAM-101 for SCD in the phase 1/2 BEACON-101 study.
Bone Marrow-Derived Mesenchymal Stem Cells Safe in ALS
ALSFRS-R and FVC values were stable 3 months after treatment but significantly decreased 6 months after treatment, warranting further investigation.
Advantages of T-Cell Immunotherapy Over CAR T-Cells
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.
CAR T: A Novel Approach for Mantle Cell Lymphoma
New treatment options expand management of relapsed or refractory disease.
Advantages of Concurrently Investigating Gene Therapies in Dogs and Humans
Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.
IND Accepted for HER2+ Gastric and Gastroesophageal Junction Cancer Cell Therapy
CYNK-101 is set to be evaluated in combination with standard chemotherapy, trastuzumab and pembrolizumab in a phase 1/2a study.
CAR T and Other Emerging Therapies in R/R Multiple Myeloma: Kenneth H. Shain, MD, PhD
The hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.
Study Aims to Gain Insights into Genetics of Glaucoma
The study is aiming to gain insight into glaucoma in African American populations.
CRISPR/Cas9-Edited CAR and NK Cell Therapies Show Preclinical Efficacy
CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.
Utility of CAR T-Cell Therapy in Relapsed Multiple Myeloma: Thomas G. Martin, MD
The co-leader of Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center discussed he utility of CAR T-cell therapy in late relapsed multiple myeloma.
GeneTherapyLive’s Weekly Rewind – November 26, 2021
Review top news and interview highlights from the week ending November 26, 2021.
